- Home
- CRVO vs FSEA Comparison
CRVO vs FSEA Comparison
Compare CRVO & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- FSEA
- Stock Information
- Founded
- CRVO 2001
- FSEA 1890
- Country
- CRVO United States
- FSEA United States
- Employees
- CRVO N/A
- FSEA N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- CRVO Health Care
- FSEA Finance
- Exchange
- CRVO Nasdaq
- FSEA Nasdaq
- Market Cap
- CRVO 67.4M
- FSEA 54.1M
- IPO Year
- CRVO N/A
- FSEA N/A
- Fundamental
- Price
- CRVO $7.45
- FSEA $11.53
- Analyst Decision
- CRVO Strong Buy
- FSEA
- Analyst Count
- CRVO 6
- FSEA 0
- Target Price
- CRVO $19.17
- FSEA N/A
- AVG Volume (30 Days)
- CRVO 109.4K
- FSEA 4.6K
- Earning Date
- CRVO 11-11-2025
- FSEA 11-07-2025
- Dividend Yield
- CRVO N/A
- FSEA N/A
- EPS Growth
- CRVO N/A
- FSEA N/A
- EPS
- CRVO N/A
- FSEA N/A
- Revenue
- CRVO $7,776,968.00
- FSEA $14,095,000.00
- Revenue This Year
- CRVO N/A
- FSEA N/A
- Revenue Next Year
- CRVO N/A
- FSEA N/A
- P/E Ratio
- CRVO N/A
- FSEA N/A
- Revenue Growth
- CRVO N/A
- FSEA 30.26
- 52 Week Low
- CRVO $1.80
- FSEA $9.00
- 52 Week High
- CRVO $16.94
- FSEA $11.95
- Technical
- Relative Strength Index (RSI)
- CRVO 38.31
- FSEA 50.16
- Support Level
- CRVO $7.03
- FSEA $11.50
- Resistance Level
- CRVO $8.38
- FSEA $11.60
- Average True Range (ATR)
- CRVO 0.54
- FSEA 0.06
- MACD
- CRVO -0.10
- FSEA -0.00
- Stochastic Oscillator
- CRVO 11.00
- FSEA 25.66
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.